Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas

Inclusion Criteria: * Histological or cytological proof of hepatocellular or biliary tract carcinomas, not amenable to curative resection or transplantation. * Prior cancer treatment completed at least 30 days prior to being registered for protocol therapy and recovered from the acute toxicity effects of the regimen. * Patients may have had radiofrequency ablation, cryosurgery or embolization, but must have documented progressive disease with the involved lesion, or at least one previously untreated lesion. * Patients may have had ≤ 2 prior chemotherapy regimens. * Prior radiation therapy allowed to \< 25% of the bone marrow at least 30 days prior to being registered for protocol therapy. * Patients with biliary obstruction must have percutaneous transhepatic drainage or endoscopic stent placement prior to starting study treatment. * Patients with a history of malignancy are eligible provided they have been curatively treated and demonstrate no evidence for recurrence of that cancer. * Peripheral neuropathy ≤ grade 1. * Patients must agree to abstain from frozen or fresh grapefruit or grapefruit juice for 5 days prior to, and during treatment. * Patients must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) while on treatment and for a 12 week period thereafter. * Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy. * Written informed consent and HIPAA authorization for release of personal health information. * Age ≥ 18 years at time of consent. Exclusion Criteria: * No previous treatment with EGFR inhibitors. * No treatment with any investigational agent within 30 days prior to being registered for protocol therapy. * No symptomatic brain metastasis. A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis, no longer require corticosteroids, and are asymptomatic. * No Child-Pugh B or C liver cirrhosis. * No active corneal erosions or history of abnormal corneal sensitivity test. * No history of aneurysm or arteriovenous malformation. * No hemorrhage/bleeding event \> CTCAE Grade 3 within 30 days prior to begin registered for protocol therapy. * No clinically significant infections as judged by the treating investigator. * No condition that impairs patient's ability to swallow whole pills. * No history of hypersensitivity to docetaxel or other drugs formulated with polysorbate 80. * Females must not be breastfeeding. * Patients who cannot avoid the following medications will be ineligible for the trial: midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, phenobarbital, phenytoin, carbamazepine, and rifampin (induction) and anti-retrovirals (including ritonavir, saquinavir).